Dimethylsulfoxide excerbates cisplatin-induced cytotoxicity in Ehrlich ascites carcinoma cells

Cancer Cell International

Lateef M. Khan⁴  Mohamed A. M. Osman⁵  Fatemah Kamel⁴  Wafaa S. Ramadan³  Mohamed F. ElShal¹  Sameer E. Al-Harthy⁴  Zoheir A. Damanhouri⁴  Ali A. Alqahtani⁴  Abdel-Moneim M. Osman² 

[1] Molecular Biology Department, Genetic Engineering and Biotechniology Department, Minoufia University, Minoufia, Egypt;Pharmacology Unit, National Cancer Institute, Cairo University, Giza, Egypt;Anatomy Department, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia;Pharmacology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia;College of Dentistry, Russian University, Cairo, Egypt

关键词: Cytotoxicity;    Dimethylsulfoxide;    Cisplatin;   

Others  :  1233576
DOI  :  10.1186/s12935-015-0258-1

 received in 2015-03-30, accepted in 2015-10-14,  发布年份 2015

【 摘 要 】

Background

Cisplatin (CIS) is a potent antineoplastic agent with high therapeutic efficacy against many kinds of tumors. Its use is limited by its nephrotoxicity. The aim of this work was to minimize cisplatin effective dose and the possible reduction ofits severe side effects. The present study was designed to assess the role of sulfur containing agent dimethyl sulfoxide (DMSO) on sensitization of mammary carcinoma, Ehrlich ascites carcinoma (EAC), to the action of cisplatin and at the same time the possible protective effect against cisplatin induced nephrotoxicity in experimental animals.

Methods

To evaluate these effects we have explored the cisplatin effect on the survival time of tumor-bearing animals, tumor weight, cisplatin cellular uptake, apoptosis induction and cell cycle distribution and renal function in presence and absence of DMSO.

Results

Cisplatin at dose of 4.5 mg/kg increased the mean survival time of tumor bearing mice to 37 days compared with tumor bearing control mice. Pretreatment of tumor bearing mice with DMSO 50 % (2 ml/kg equal to 1 gm/kg) 2 h. before cisplatin showed a significant increase in their mean survival time 43 days compared to cisplatin treated animals. DMSO pretreatment retained rat’s serum urea and creatinine levels to normal compared to animals treated with cisplatin alone.

Conclusion

DMSO pretreatment enhanced the cytotoxic activity of cisplatin against the growth of EAC in vivo and showed protective effects against cisplatin-induce nephrotoxicity.

【 授权许可】

   
2015 Osman et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

Fig.4.

Fig.5.

Fig.6.

【 参考文献 】

• [1]Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002; 42:317-325.
• [2]Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1998; 34:1535-1542.
• [3]Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998; 34:1522-1534.
• [4]Sanmartin-Suarez C, Soto-Otero R, Sanchez-Sellero I, Mendez-Alvarez E. Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants. J Pharmacol Toxicol Methods. 2011; 63:209-215.
• [5]Jacob SW, Bischel M, Herschler RJ. Dimethyl sulfoxide: effects on the permeability of biologic membranes (preliminary report). Curr Ther Res Clin Exp. 1964; 6:193-198.
• [6]Stoughton RB, Fritsch W. Influence of dimethylsulfoxide (DMSO) on human percutaneous absorption. Arch Dermatol. 1964; 90:512.
• [7]Kligman AM. Dimethyl sulfoxide. 2. JAMA. 1965; 193: 923–8 (concl).
• [8]Uribe PM, Mueller MA, Gleichman JS, Kramer MD, Wang Q, Sibrian-Vazquez M, Strongin RM, Steyger PS, Cotanche DA, Matsui JI. Dimethyl sulfoxide (DMSO) exacerbates cisplatin-induced sensory hair cell death in zebrafish (Danio rerio). PLoS One. 2014; 8:e55359.
• [9]Donenko FV, Efferth T, Mattern J, Moroz LV, Volm M. Resistance to doxorubicin in tumor cells in vitro and in vivo after pretreatment with verapamil. Chemotherapy. 1991; 37:57-61.
• [10]Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O’flaherty JD, Fennell DA, Richard D, O’leary JJ, O’byrne KJ. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 2013; 8:e54193.
• [11]Pozarowiski P, Darzynkiewicz Z. Analysis of cell cycle by flowcytometry method. Mol Biol. 2004; 281:301-311.
• [12]Taussky RW, Taussky HH. ON the colorimetric determination of creatinine by the jaffe reaction. J Biol Chem. 1945; 10.
• [13]Fawcett JK, Scott JE. A rapid and precise method for the determination of urea. J Clin Pathol. 1960; 13:156-159.
• [14]Jones MM, Basinger MA, Field L, Holscher MA. Coadministration of dimethyl sulfoxide reduces cisplatin nephrotoxicity. Anticancer Res. 1991; 11:1939-1942.
• [15]Trubiani O, Ciancarelli M, Rapino M, di Primio R. Dimethyl sulfoxide induces programmed cell death and reversible G1 arrest in the cell cycle of human lymphoid pre-T cell line. Immunol Lett. 1996; 50:51-57.
• [16]Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ. In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry. 1985; 24:7533-7540.
• [17]Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther. 1987; 34:155-166.
• [18]Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4:307-320.
• [19]Liu J, Yoshikawa H, Nakajima Y, Tasaka K. Involvement of mitochondrial permeability transition and caspase-9 activation in dimethyl sulfoxide-induced apoptosis of EL-4 lymphoma cells. Int Immunopharmacol. 2001; 1:63-74.
• [20]Gurtovenko AA, Anwar J. Modulating the structure and properties of cell membranes: the molecular mechanism of action of dimethyl sulfoxide. J Phys Chem B. 2007; 111:10453-10460.
• [21]Sundquist WI, Ahmed KJ, Hollis LS, Lippard SJ. Solvolysis reactions of cis- and trans-diamminedichloroplatinum(II) in dimethyl sulfoxide. Structural characterization and DNA binding of trans-bis(ammine)chloro(DMSO)platinum(1+). Inorg Chem. 1987; 26:1524-1528.
• [22]Pommier RF, Woltering EA, Milo G, Fletche WS. Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro. Am J Obstet Gynecol. 1988; 159:848-852.
• [23]Hall MD, Telma KA, Chang KE, Lee TD, Madigan JP, Lloyd JR, Goldlus IS, Hoeschele JD, Gottesman MM. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res. 2014; 74:3913-3922.
• [24]Takase K, Sawai M, Yamamoto K, Yata J, Takasaki Y, Teraoka H, Tsukada K. Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: kinetics of the arrest and expression of the cell cycle marker proliferating cell nuclear antigen in Raji cells. Cell Growth Differ. 1992; 3:515-521.
• [25]Yan X, Fraser M, Qiu Q, Tsan BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol. 2006; 102:348-355.
• [26]Ponzio G, Loubat A, Rochet N, Turchi L, Rezzonico R, FarahiFar D, Dulic V, Rossi B. Early G1 growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21[CIP1] induction. Oncogene. 1998; 17:1159-1166.
• [27]Zhang JG, Lindup WE. Differential effects of cisplatin on the production of NADH-dependent superoxide and the activity of antioxidant enzymes in rat renal cortical slices in vitro. Pharmacol Toxicol. 1996; 79:191-198.
• [28]Ali BH, Mousa HM. Effect of dimethyl sulfoxide on gentamicin-induced nephrotoxicity in rats. Hum Exp Toxicol. 2001; 20:199-203.
• [29]Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol. 2003; 65:1035-1041.